CAR T-Cell Therapy

Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.

During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.

In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the early and encouraging findings from a novel bispecific antibody for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.

Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.

Deepu Madduri, MD, discusses how chimeric antigen receptor T-cell therapy is used for patients with multiple myeloma.

Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Early data in mouse models have demonstrated that the novel approach of providing CD2 costimulation to CAR T cells in trans could reeestablish the efficacy of treatment in patients with CD58 mutations

The off-the-shelf CAR T-cell therapy ALLO-715, which targets BCMA, demonstrated responses as treatment of patients with heavily pretreated relapsed/refractory multiple myeloma in a first-in-human clinical trial.

Loretta J. Nastoupil, MD, discusses the use of off-the-shelf chimeric antigen receptor T-cell products for the treatment of patients with diffuse large B-cell lymphoma and other cancers.

Chimeric antigen receptor T-cell therapy with the novel agent CTX110 showed promising early efficacy and safety as treatment of patients with relapsed or refractory CD19-positive B-cell malignancies who were treated in the phase 1 CARBON clinical trial.

CART-PSMA-TGFβRd as adoptive chimeric antigen receptor T-cell therapy administered as treatment of patients with metastatic castration-resistant prostate cancer appears safe and feasible.

Natalie S. Callander, MD, discusses the role of CAR T-cell therapy as treatment of patients with multiple myeloma.

In the past 5 years, 3 new options have emerged to treat patients with relapsed/ refractory acute lymphoblastic leukemia, providing hope for patients with this disease but also raising clinical questions.

The FDA granted Orphan Drug designation to the humanized anti-claudin18.2 autologous chimeric antigen receptor T-cell agent, CT041, for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma.

In an interview with Targeted Oncology, Tanja Gruber, MD, PhD, discussed the advances she has observed in recent years for the treatment of pediatric patients, including the evolving role of CAR T-cell therapy.

C. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.

During a presentation at the 2020 Society of Hematologic Oncology Virtual Annual Meeting, Andrzej Jakubowiak, MD, PhD, reviewed clinical trials of CAR T-cell therapy in multiple myeloma and the emergence of CAR T cells against SMALF7, GPRC5D, and CD229.

In an interview with Targeted Oncology, David E. Gilham, PhD, discussed the findings from the single vector multiplexed short-hairpin RNA approach to concurrently knockdown the expression of multiple genes in chimeric antigen receptor T cells when used as treatment of patients with cancer.

A single-center experience demonstrated that certain pre- and post-treatment characteristics may predict outcomes for patients with diffuse large B-cell lymphoma following treatment with a chimeric antigen receptor T-cell therapy.

The FDA has granted a fast track designation to PBCAR0191, a CD19-directed allogeneic chimeric antigen receptor T-cell therapy, for the treatment of patients with advanced B-cell precursor acute lymphoblastic leukemia.

An investigator-initiated trial of a humanized CD19-directed chimeric antigen receptor T-cell therapy has been completed, demonstrating the therapy may be a safe and effective treatment for patients with hematologic malignancies.

Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.

"These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen."

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.